Decoy Therapeutics rises as Gates Foundation backs antiviral drug access

Decoy Therapeutics

13/01/2026 13:24

** Shares of drug developer Decoy Therapeutics DCOY.O rise 6.99% to $0.872 premarket

** Co says it has reached agreement with Gates Foundation to develop manufacturing platform for antiviral drugs

** Platform aims to make antivirals widely available in low- and middle-income countries, co says

** Technology called IMP3ACT enables rapid design and production of drugs for viruses such as flu and people with weakened immune systems, co adds

** Co plans to validate platform with experimental nasal spray to prevent coronavirus infections in immunocompromised people

** Lead antiviral candidate expected to be submitted to U.S. regulators within a year, DCOY says

** As of last close, stock down ~97% over past year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))